DeepMed Research

KYOWA KIRIN CO., LTD.

🇯🇵Japan

Country: 🇯🇵Japan

Ownership: Public, Subsidiary

Established: 1949-07-01

Employees: 5.9K

Market Cap: -

Website: http://www.kyowa-kirin.co.jp

Clinical Trials

A Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study of ARQ 197 Plus Erlotinib Versus Placebo Plus Erlotinib

Phase 3

Terminated

Conditions: Non-small-cell Lung Cancer

Interventions: Drug: Placebo and Erlotinib
Drug: ARQ 197 and Erlotinib

First Posted Date: 2011-06-21

Last Posted Date: 2016-12-07

Lead Sponsor: Kyowa Kirin Co., Ltd.

Registration Number: NCT01377376

A Study of LY2523355 in Patients With Solid Cancer

Phase 1

Completed

Conditions: Solid Tumors

Interventions: Drug: LY2523355

First Posted Date: 2011-05-23

Last Posted Date: 2013-01-28

Lead Sponsor: Kyowa Kirin Co., Ltd.

Target Recruit Count: 18

Registration Number: NCT01358019

A Repeated Study of KRN23 in Adults With X-Linked Hypophosphatemia

Phase 1

Completed

Conditions: X-linked Hypophosphatemia

Interventions: Drug: KRN23

First Posted Date: 2011-04-22

Last Posted Date: 2024-06-18

Lead Sponsor: Kyowa Kirin Co., Ltd.

Target Recruit Count: 29

Registration Number: NCT01340482

Locations: 🇺🇸
University of California, San Francisco Medical Center, San Francisco, California, United States
🇺🇸
Clinical Research Center, Indiana University School of Medicine, Indianapolis, Indiana, United States
🇺🇸
Yale University School of Medicine, New Haven, Connecticut, United States

and more 3 locations

A Comparative Study of KW-2246

Phase 3

Completed

Conditions: Cancer Related Pain (Breakthrough Pain)

Interventions: Drug: KW-2246
Drug: Placebo

First Posted Date: 2011-03-31

Last Posted Date: 2017-03-08

Lead Sponsor: Kyowa Kirin Co., Ltd.

Target Recruit Count: 42

Registration Number: NCT01326689

Study of Anti-HB-EGF Antibody KHK2866 in Subjects With Advanced Solid Tumors and Ovarian Cancer

Phase 1

Terminated

Conditions: Neoplasms
Fallopian Tube Neoplasms
Primary Peritoneal Neoplasm
Ovarian Neoplasms

Interventions: Biological: KHK2866
Drug: Gemcitabine and Carboplatin
Drug: pegylated liposomal doxorubicin
Drug: paclitaxel

First Posted Date: 2011-01-19

Last Posted Date: 2024-04-26

Lead Sponsor: Kyowa Kirin Co., Ltd.

Target Recruit Count: 22

Registration Number: NCT01279291

Locations: 🇺🇸
USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
Cedar Sinai-Samuel Oschin Comprehensive Cancer Institute, Los Angeles, California, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

and more 4 locations

A Study of ARQ 197 in Combination With Erlotinib

Phase 1

Completed

Conditions: Advanced/Recurrent Non-small-cell Lung Cancer

Interventions: Drug: ARQ 197 and Erlotinib

First Posted Date: 2010-12-02

Last Posted Date: 2017-03-15

Lead Sponsor: Kyowa Kirin Co., Ltd.

Target Recruit Count: 9

Registration Number: NCT01251796

Extension Study in Subjects Who Relapsed After Complete Response on Study KW-0761-001

Phase 2

Completed

Conditions: Peripheral T-cell Lymphoma
Cutaneous T-cell Lymphoma

Interventions: Biological: KW-0761

First Posted Date: 2010-10-22

Last Posted Date: 2024-04-25

Lead Sponsor: Kyowa Kirin Co., Ltd.

Target Recruit Count: 1

Registration Number: NCT01226472

Locations: 🇺🇸
Stanford University, Stanford, California, United States

Safety, Tolerability, and Efficacy Study in Subjects With Advanced or Metastatic Breast Cancer

Phase 1

Terminated

Conditions: Breast Cancer

Interventions: Drug: KW-2450 in combination with lapatinib and letrozole

First Posted Date: 2010-09-10

Last Posted Date: 2024-04-25

Lead Sponsor: Kyowa Kirin Co., Ltd.

Target Recruit Count: 11

Registration Number: NCT01199367

Locations: 🇺🇸
Associates in Hematology-Oncology, Los Angeles, California, United States
🇺🇸
Clinical Oncology Associates, Farmington Hills, Michigan, United States
🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

and more 2 locations

A Phase 3 Study of OPC-262 in Patients With Type 2 Diabetes

Phase 3

Completed

Conditions: Diabetes, Type 2

Interventions: Drug: OPC-262

First Posted Date: 2010-09-01

Last Posted Date: 2014-01-08

Lead Sponsor: Kyowa Kirin Co., Ltd.

Target Recruit Count: 450

Registration Number: NCT01193179

Study of KW-0761 in Subjects With CCR4-positive Peripheral T/NK-cell Lymphoma

Phase 2

Completed

Conditions: Peripheral T/NK-cell Lymphoma

Interventions: Biological: KW-0761

First Posted Date: 2010-09-01

Last Posted Date: 2017-03-03

Lead Sponsor: Kyowa Kirin Co., Ltd.

Target Recruit Count: 38

Registration Number: NCT01192984

Locations: 🇯🇵
University Hospital, Kyoto Prefectural University of Medicine, Kyoto, Japan
🇯🇵
Nagasaki University Hospital, Nagasaki, Japan
🇯🇵
Okayama University Hospital, Okayama, Japan

and more 12 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy